Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells.
Alessandro NiniMichèle Janine HoffmannRita LampignanoRobert Große SiemerGuus van DalumTibor SzarvasCristina Lopez CotareloWolfgang Arthur SchulzDieter NiederacherHans NeubauerNikolas Hendrik StoeckleinGuenter NiegischPublished in: Cytometry. Part B, Clinical cytometry (2020)
Detection rate of CTCs by EpCAM in UC is poor, even in metastatic patients. Because of its widespread expression, particularly in patients with high risk of metastasis, detection of HER2 could improve identification of UC CTCs, which is why combined detection using antibodies for EpCAM and HER2 may be beneficial.
Keyphrases